| Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. | |
| | |
MedLine Citation:
|
PMID: 18570597 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The management of obese hypertensive subjects may require the administration of anti-obesity and antihypertensive drugs. Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure and heart rate. The primary end-points of this study were an evaluation of the effect of sibutramine together with a verapamil sustained release/trandolapril combination tablet versus verapamil sustained release/trandolapril alone on the blood pressure and heart rate in obese hypertensive patients. RESEARCH DESIGN/METHODS: Patients received a low-fat low-calorie diet and were randomly allocated to open-label verapamil sustained release/trandolapril 180/2 mg (n = 26) or sibutramine 10 mg together with verapamil sustained release/trandolapril 180/2 mg (n = 28) daily for 6 months. RESULTS: Significant reductions in the subjects' systolic blood pressure and diastolic blood pressure were observed in both groups (p < 0.01 versus baseline). At 6 months a greater fall in blood pressure was observed in the sibutramine/verapamil sustained release/trandolapril group compared with the verapamil sustained release/trandolapril group (systolic blood pressure 21.9 +/- 8.1 versus 15.9 +/- 12.3 mmHg and diastolic blood pressure 15.7 +/- 8.1 versus 9.1 +/- 9.9 mmHg) but this was only significant (p = 0.03) for diastolic blood pressure. The subjects' heart rate did not change significantly in any group. No significant sibutramine-associated attenuation of blood pressure reduction was observed during the study. The sibutramine/verapamil sustained release/trandolapril treatment resulted in significantly greater improvement in the subjects' anthropometric variables, homeostasis model assessment and lipid profiles compared with verapamil sustained release/trandolapril administration. The subjects' small dense low-density lipoprotein cholesterol, high-sensitivity C-reactive protein and visfatin plasma levels were only measured in the sibutramine/verapamil sustained release/trandolapril group (all decreased by p < 0.05 versus baseline). CONCLUSIONS: The sibutramine/verapamil sustained release/trandolapril combination in obese hypertensive patients significantly reduced their blood pressure and improved their anthropometric and metabolic variables without affecting the heart rate. |
| | |
Authors:
|
E Nakou; T D Filippatos; E N Liberopoulos; A D Tselepis; D N Kiortsis; D P Mikhailidis; M S Elisaf |
Related Documents
:
|
14575277 - Effects of manidipine and nifedipine on blood pressure and renal function in patients w... 6599697 - Pressor factors and cardiovascular pressor responsiveness after short-term antihyperten... 3767537 - Management of perioperative hypertension using sublingual nifedipine. experience in eld... 2864857 - Nifedipine in combination therapy for chronic hypertension. a review. 1410177 - Respiratory sinus arrhythmia and cardiovascular responses to stress. 20481727 - Glassy dynamics under superhigh pressure. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 9 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2008 Jul |
Date Detail:
|
Created Date: 2008-06-23 Completed Date: 2008-08-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 1629-39 Citation Subset: IM |
Affiliation:
|
University of Ioannina, Department of Internal Medicine, School of Medicine, 45 110 Ioannina, Greece. egepi@cc.uoi.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antihypertensive Agents / administration & dosage, therapeutic use* Appetite Depressants / administration & dosage, therapeutic use* Blood Pressure / drug effects Body Weights and Measures C-Reactive Protein / analysis Cyclobutanes / administration & dosage, therapeutic use* Delayed-Action Preparations Diet Drug Combinations Drug Therapy, Combination Female Heart Rate / drug effects Humans Hypertension / complications, drug therapy* Indoles / administration & dosage, therapeutic use* Lipids / blood Male Nicotinamide Phosphoribosyltransferase / drug effects Obesity / complications, drug therapy* Verapamil / administration & dosage, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Appetite Depressants; 0/Cyclobutanes; 0/Delayed-Action Preparations; 0/Drug Combinations; 0/Indoles; 0/Lipids; 106650-56-0/sibutramine; 52-53-9/Verapamil; 87679-37-6/trandolapril; 9007-41-4/C-Reactive Protein; EC 2.4.2.12/Nicotinamide Phosphoribosyltransferase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Socioeconomic inequalities of tuberculosis in India.
Next Document: Quality of life in hypertension management using olmesartan in primary care.